Journal Mobile Options
Table of Contents
Vol. 42, Suppl. 1, 2000
Issue release date: November 2000

Differential Efficacy of Lithium and Carbamazepine in the Prophylaxis of Bipolar Disorder: Results of the MAP Study

Kleindienst N. · Greil W.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

In a randomized clinical trial with an observation period of 2.5 years, the differential efficacy of lithium versus carbamazepine was compared in 171 bipolar patients (DSM-IV). In order to investigate the efficacy of the two drugs in clearly defined subsamples, a series of subgroup analyses was carried out. First, patients with a bipolar I disorder (n = 114) were analyzed separately. In these patients, lithium was superior to carbamazepine. In contrast, carbamazepine was at least equally as efficacious as lithium in the subsample of patients with bipolar II disorder or bipolar disorder not otherwise specified (n = 57). In a second analysis on differential efficacy, the whole sample was subdivided into a classical subgroup (bipolar I patients without mood-incongruent delusions and without comorbidity; n = 67) and a nonclassical subgroup including all other patients (n = 104). Classical bipolar patients had a significantly lower hospitalization rate under lithium than under carbamazepine prophylaxis (26 vs. 62%, p = 0.012). For the nonclassical group, a tendency in favor of carbamazepine was found. In a third step, we analyzed the impact of episode sequence on differential efficacy. In a global view, the episode sequence prior to the index episode was not correlated to differential efficacy. Our results might, however, indicate that patients with an episode sequence of mania-depression-free interval responded better to lithium. Besides differential efficacy, suicidal behavior and patients’ satisfaction with treatment were investigated. Regarding suicidal behavior, a trend in favor of lithium was found. The data on patients’ satisfaction were significantly in favor of carbamazepine. In conclusion, lithium appears to be superior to carbamazepine in classical bipolar cases and might have additional impact on proneness to suicide. The distinctly larger group of patients with nonclassical features might profit more from carbamazepine which seems to be well accepted by the patients. Hence, treatment alternatives to lithium are desirable for the majority of bipolar patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Stoll AL, Tohen M, Baldessarini RJ, Goodwin DC, Stein S, Katz S, Geenens D, Swinson RP, Goethe JW, McGlashan T: Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972–1988. Am J Psychiatry 1993;150:1668–1673.
  2. Grof P: Has the effectiveness of lithium changed? Impact of the variety of lithium’s effects. Neuropsychopharmacology 1998;19:183–188.
  3. Grof P, Alda M: Discrepancies in the efficacy of lithium. Arch Gen Psychiatry 2000;57:191.

    External Resources

  4. Dunner DL: Differential diagnosis of bipolar disorder. J Clin Psychopharmacol 1992;12:7S–12S.
  5. Dunner DL: Bipolar Disorder in DSM-IV: Impact of inclusion of rapid cycling as a course modifier. Neuropsychopharmacology 1998;19:189–193.
  6. Akiskal HS: The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV. J Clin Psychopharmacol 1996;16(suppl 1):4S–14S.
  7. Zarate CA Jr, Tohen M, Baraibar G, Zarate SB, Baldessarini RJ: Shifts in hospital diagnostic frequencies: Bipolar disorder subtypes, 1981–1993. J Affect Disord 1997;43:79–84.
  8. Goodwin FK, Ghaemi SN: Understanding manic-depressive Illness. Arch Gen Psychiatry 1998;55:23–25.
  9. Post RM, Ketter TA, Dennicoff K, Pazzaglia PJ, Leverich GS, Marangell AM, Callalian AM, George MS, Frye MA: The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 1996;128:115–129.
  10. Gershon S, Soares JC: Current therapeutic profile of lithium. Arch Gen Psychiatry 1997;54:16–20.
  11. Schou M: Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 1998;31:210–215.

    External Resources

  12. Emrich HM, Okuma T, Müller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam, Excerpta Medica, 1984.
  13. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI: Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines. J Clin Psychopharmacol 1992;12:42S–52S.
  14. Calabrese JR, Rapport DJ, Kimmel SE, Reece B, Woyshville MJ: Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry 1993;38:S57–S61.

    External Resources

  15. Calabrese JR, Bowden C, Woyshville MJ: Lithium and the anticonvulsants in the treatment of bipolar disorder; in Bloom FE, Kupfer DJ (eds): Psychopharmacology. The Fourth Generation of Progress. New York, Raven Press, 1995, pp 1099–1111.
  16. Dardennes R, Even C, Bange F, Heim A: Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder. A meta-analysis. Br J Psychiatry 1995;166:378–381.

    External Resources

  17. Post RM, Denicoff K, Frye MA, Leverich GS: Re-evaluating carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry 1997;170:202–204.
  18. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P: Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:522–527.
  19. Zarate CA Jr, Tohen JM, Banov MD, Weiss MK, Cole JO: Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108–112.
  20. Sarfati Y, Spadone C, Vanelle JM, Loo H: Inhibiteurs calciques et lithium dans le traitement prophylactique de la maladie maniaco-dépressive. Encéphale 1996;22:149–153.

    External Resources

  21. Schaffer CB, Schaffer LC: Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997;154:291–292.
  22. Tohen M, Zarate CA Jr: Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998;59(suppl 1): 38–48.
  23. Keck PE Jr, McElroy SJ, Strakowski SM: Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998;59(suppl 6): 74–81.
  24. Marcotte D, Gullick A: Use of topiramte, a new antiepileptic, as a mood stabilizer. J Affect Disord 1998;50:245–251.
  25. Grunze H, Schlösser S, Amann B, Walden J: Anticonvulsant drugs in bipolar disorder. Dialogues Clin Neurosci 1999;1:24–40.
  26. Solomon DA, Keitner DI, Miller IW, Shea MT, Keller MB: Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 1995;56:5–13.
  27. Maarbjerg K, Aagaard J, Vestergaard P: Adherence to lithium prophylaxis. I. Clinical predictors and patient’s reasons for nonadherence. Pharmacopsychiatry 1988;21:121–125.
  28. Guscott R, Taylor L: Lithium prophylaxis in recurrent affective illness. Br J Psychiatry 1994;164:741–746.

    External Resources

  29. Kupfer DJ: Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl 5):28–34.
  30. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766–771.
  31. Greil W, Ludwig-Mayerhofer W, Steller B, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T: The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J Affect Disord 1993;28:257–265.
  32. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T: Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: A randomised study. J Affect Disord 1996;40:179–190.

    External Resources

  33. Spitzer RL, Endicott J, Robins E: Forschungsdiagnosekriterien (RDC). Weinheim, Belz, 1982.
  34. Mantel N: Chi-square tests with one degree of freedom; extension of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690–700.
  35. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  36. Tarone RE, Ware J: On distribution-free tests for equality of survival distributions. Biometrica 1977;64:156–160.
  37. Montgomery SA, Dunbar G: Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189–195.
  38. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18:455–460.
  39. Greil W, Kleindienst N: The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999;14:277–281.
  40. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry 1996;29:103–107.
  41. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T: Lithium versus carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. Eur Arch Psychiatry Clin Neurosci 1997;247:42–50.

    External Resources

  42. Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: A randomized study. J Affect Disord 1997;43:151–161.

    External Resources

  43. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM: The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987;150:180–182.

    External Resources

  44. Oxtoby A, Jones A, Robinson M: Is your ‘double-blind’ design truly double-blind? Br J Psychiatry 1989;155:700–701.

    External Resources

  45. Baastrup PC, Schou M: Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967;16:162–172.

    External Resources

  46. Hanus H, Zapletalek M: The prophylactic lithium treatment in affective disorders and the possibilities of the outcome prediction. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1984;27:5–75.

    External Resources

  47. Kusalic M, Engelsmann F: Predictors of lithium treatment responsiveness in bipolar patients. A two-year prospective study. Neuropsychobiology 1998;37:146–149.
  48. O’Connell RA, Mayo JA, Flatow L, Cuthbertson B, O’Brien BE: Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123–129.
  49. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic-depressive cycle and changes caused by treatments. Pharmacopsychiatry 1980;13:156–167.
  50. Haag M, Heidorn A, Haag H, Greil W: Response to stabilising lithium therapy and sequence of affective polarity. Pharmacopsychiatry 1986;19:278–279.
  51. Grof E, Haag M, Grof P, Haag H: Lithium response and the sequence of episode polarities: Preliminary report on a Hamilton sample. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:199–203.
  52. Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ: Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996;16(suppl 1): 24S–31S.
  53. Baldessarini RJ, Tondo MD: Does lithium treatment still work? Arch Gen Psychiatry 2000;57:187–190.
  54. Schou M, Hansen HE, Thomsen K, Vestergaard P: Lithium treatment in Aarhus. 2. Risk of renal failure and of intoxication. Pharmacopsychiatry 1989;22:101–103.

    External Resources

  55. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990.
  56. Kleindienst N, Greil W, Rüger B, Möller HJ: The prophylactic efficacy of lithium – Transient or persistent? Eur Arch Psychiatry Clin Neurosci 1999;249:144–149.
  57. Lambert PA: Acute and prophylactic therapies of patients with affective disorders using valpromide (Dipropylacetamide); in Emrich HM, Okuma T, Müller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam, Excerpta Medica, 1984:33–44.
  58. Hayes S: Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989;50(suppl): 35–39.
  59. Juckel G, Hegerl U, Mavrogiorgou P, Gallinat J, Mager T, Tigges P, Dresel S, Schröter A, Stotz G, Meller I, Greil W, Möller HJ: Clinical and biological findings in a case with 48-hour bipolar ultra-rapid cycling before and under valproate treatment. J Clin Psychiatry 2000;61:585–591.

    External Resources

  60. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM: Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37–42.
  61. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918–924.
  62. Bowden CL: Predictors of response to divalproex and lithium. J Clin Psychiatry 1995;56(suppl 3): 25–30.
  63. Calabrese JR, Fatemi SH, Woyshville MJ: Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996;153:1236.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50